Insider · CIK 0001274225
LANGER DENNIS
Reports to the SEC for 11 companies · ASHBURN, VA
Transactions
50
Companies
11
Filings
14
CIK
0001274225
Forms 4 and 5
Insider transactions
| Date | Company | Value |
|---|---|---|
| 2026-08-27 | QNRXQuoin Pharmaceuticals Ltd.A Award | +$178K |
| 2026-02-04 | QNRXQuoin Pharmaceuticals Ltd. · Share Option (Right to Buy)A Award | — |
| 2025-10-14 | QNRXQuoin Pharmaceuticals Ltd. · Series J Warrants (Right to Buy)P Purchase | — |
| 2025-10-14 | QNRXQuoin Pharmaceuticals Ltd. · Series I Warrants (Right to Buy)P Purchase | — |
| 2025-10-14 | QNRXQuoin Pharmaceuticals Ltd. · Series K Warrants (Right to Buy)P Purchase | — |
| 2025-10-14 | QNRXQuoin Pharmaceuticals Ltd. · Series H Warrants (Right to Buy)P Purchase | — |
| 2025-10-14 | QNRXQuoin Pharmaceuticals Ltd.P Purchase | +$129K |
| 2025-08-21 | QNRXQuoin Pharmaceuticals Ltd. · Share Option (Right to Buy)A Award | — |
| 2025-05-29 | QNRXQuoin Pharmaceuticals Ltd. · Share Option (Right to Buy)A Award | — |
| 2024-12-09 | QNRXQuoin Pharmaceuticals Ltd. · Share Option (Right to Buy)A Award | — |
| 2024-06-07 | QNRXQuoin Pharmaceuticals Ltd.S Sale | −$217.404 |
| 2023-10-26 | QNRXQuoin Pharmaceuticals Ltd. · Share Option (Right to Buy)A Award | — |
| 2022-06-02 | MYGNMYRIAD GENETICS INCA Award | — |
| 2021-12-08 | ERNAErnexa Therapeutics Inc. · Stock OptionA Award | — |
| 2021-08-03 | MYGNMYRIAD GENETICS INCM Exercise/Conversion | +$762K |
| 2021-08-03 | MYGNMYRIAD GENETICS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion | — |
| 2021-08-03 | MYGNMYRIAD GENETICS INCS Sale | −$1.04M |
| 2021-06-03 | MYGNMYRIAD GENETICS INCA Award | — |
| 2020-12-04 | MYGNMYRIAD GENETICS INCA Award | — |
| 2019-12-05 | MYGNMYRIAD GENETICS INCA Award | — |
| 2019-06-20 | Dicerna Pharmaceuticals IncDirector Stock Option (right to buy)A Award | — |
| 2018-11-29 | MYGNMYRIAD GENETICS INCA Award | — |
| 2018-08-15 | Dicerna Pharmaceuticals IncS Sale | −$232K |
| 2018-08-15 | Dicerna Pharmaceuticals IncS Sale | −$381K |
| 2018-06-21 | Dicerna Pharmaceuticals IncDirector Stock Option (right to buy)A Award | — |
| 2018-06-08 | MYGNMYRIAD GENETICS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion | — |
| 2018-06-08 | MYGNMYRIAD GENETICS INCS Sale | −$538K |
| 2018-06-08 | MYGNMYRIAD GENETICS INCM Exercise/Conversion | +$291K |
| 2018-06-07 | MYGNMYRIAD GENETICS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion | — |
| 2018-06-07 | MYGNMYRIAD GENETICS INCS Sale | −$122K |
| 2018-06-07 | MYGNMYRIAD GENETICS INCM Exercise/Conversion | +$65.9K |
| 2018-06-06 | MYGNMYRIAD GENETICS INCM Exercise/Conversion | +$76.8K |
| 2018-06-06 | MYGNMYRIAD GENETICS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion | — |
| 2018-06-06 | MYGNMYRIAD GENETICS INCS Sale | −$142K |
| 2018-06-05 | MYGNMYRIAD GENETICS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion | — |
| 2018-06-05 | MYGNMYRIAD GENETICS INCM Exercise/Conversion | +$26.1K |
| 2018-06-05 | MYGNMYRIAD GENETICS INCS Sale | −$49K |
| 2018-06-04 | MYGNMYRIAD GENETICS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion | — |
| 2018-06-04 | MYGNMYRIAD GENETICS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion | — |
| 2018-06-04 | MYGNMYRIAD GENETICS INCS Sale | −$335K |
| 2018-06-04 | MYGNMYRIAD GENETICS INCM Exercise/Conversion | +$179K |
| 2018-06-04 | MYGNMYRIAD GENETICS INCS Sale | −$399K |
| 2018-06-04 | MYGNMYRIAD GENETICS INCM Exercise/Conversion | +$244K |
| 2018-06-01 | MYGNMYRIAD GENETICS INCS Sale | −$1.17M |
| 2018-06-01 | MYGNMYRIAD GENETICS INCM Exercise/Conversion | +$732K |
| 2018-06-01 | MYGNMYRIAD GENETICS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion | — |
| 2018-05-30 | MYGNMYRIAD GENETICS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion | — |
| 2018-05-30 | MYGNMYRIAD GENETICS INCS Sale | −$379K |
| 2018-05-30 | MYGNMYRIAD GENETICS INCM Exercise/Conversion | +$244K |
| 2018-05-22 | PERNIX THERAPEUTICS HOLDINGS, INC.Stock Option (right to buy)A Award | — |
Recent filings
- 4LANGER DENNIS0001104659-26-103376SEC(opens sec.gov)
- 4LANGER DENNIS0001104659-26-011613SEC(opens sec.gov)
- 4LANGER DENNIS0001104659-25-099782SEC(opens sec.gov)
- 4LANGER DENNIS0001104659-25-082511SEC(opens sec.gov)
- 4LANGER DENNIS0001104659-25-055629SEC(opens sec.gov)
- 4LANGER DENNIS0001104659-24-127230SEC(opens sec.gov)
- 4LANGER DENNIS0001104659-24-070017SEC(opens sec.gov)
- 4LANGER DENNIS0001104659-23-112558SEC(opens sec.gov)
- 4LANGER DENNIS0001628280-22-016225SEC(opens sec.gov)
- 4LANGER DENNIS0001140361-21-041284SEC(opens sec.gov)
- 4LANGER DENNIS0001274225-21-000004SEC(opens sec.gov)
- 4LANGER DENNIS0001274225-21-000002SEC(opens sec.gov)
- 4LANGER DENNIS0001274225-20-000002SEC(opens sec.gov)
- 4LANGER DENNIS0001274225-19-000002SEC(opens sec.gov)
Companies
- AUXILIUM PHARMACEUTICALS INCDirector
- CYTOGEN CORPDirector
- DELCATH SYSTEMS, INC.DirectorDCTH
- Dicerna Pharmaceuticals IncDirector
- Ernexa Therapeutics Inc.DirectorERNA
- Myrexis, Inc.Director
- MYRIAD GENETICS INCDirectorMYGN
- PERNIX THERAPEUTICS HOLDINGS, INC.Director
- Quoin Pharmaceuticals Ltd.DirectorQNRX
- SIRNA THERAPEUTICS INCDirector
- TRANSKARYOTIC THERAPIES INCDirector
Address
C/O QUOIN PHARMACEUTICALS LTD., 42127 PLEASANT FOREST COURT
ASHBURN, VA, 20148